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Abstract
Purpose To demonstrate how the current concept of
recurrent ovarian carcinoma (ROC) as a chronic disease
resulted in developments in the systemic treatment strate-
gies and outcome over time.
Methods We compared therapy type and course of a pop-
ulation-based cohort whose recurrent disease was diagnosed
from 1990 to 2006. We divided the patients into two sub-
groups depending on the year of diagnosis of ROC (group A
1990–1997, n = 70; group B 1998–2006, n = 63).
Results Both study groups showed similar results in sur-
vival (median recurrent disease-specific survival—A 18
months vs. B 19 months; P = 0.549). In group B, the
patients had significantly fewer combination therapies
administered [12.0% vs. 24.1%; odds ratio (OR) 0.43; 95%
confidence interval (CI) 0.23–0.81; P = 0.0057], received
more therapy lines (C3 lines 56.1% vs. 31.1%; OR 3.10;
95% CI 1.37–7.17; P = 0.005) and had significantly longer
times of treatment (TT) in relation to the survival time
(ST; mean TT/ST-ratio 57.5% vs. 47.5%; difference of the
mean values B–A = -10.02; 95%CI -17.99 to -2.05;
P = 0.014).
Conclusions The finding that survival of ROC patients
could not be improved over time should not necessarily be
viewed with undue pessimism regarding the general
therapy situation. In the more recent study period, a similar
outcome could be achieved with less aggressive treatment
regimens, i.e., with fewer combination therapies and with
longer treatment periods using less toxic agents. When a
disease which requires periodic chemotherapy to control
progressive course is increasingly treated with a strategy
that permits stabilization with limited cumulative toxicity,
then the requirements of a chronic disease management
have been fulfilled.
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Introduction
In the last decade, recurrent ovarian carcinoma (ROC) has
become increasingly viewed as a chronic disease process
[1–3]. There exists a vast amount of literature concerning
the systemic therapy of ROC (overview in: [1, 3–8]), but
there are no reports that focus on how this current concept
has actually altered the clinical management of the disease.
Nearly all clinical trials concentrate only on the feasibility
and impact of defined therapy options, usually in second-
line treatment situations early after the initial diagnosis of
ROC. They focus on the evaluation and comparison of
particular antineoplastic agents and drugs, but in doing so,
can only evaluate particular therapy options in pre-selected
groups of patients in certain situations. Thus, their ability to
describe the overall course of recurrent disease is limited.
The goal of this study was to depict a clear and cohesive
picture of the palliative treatment setting over a 17-year
period in an unbiased study cohort and to analyze changes
and developments in treatment strategies and patient out-
come. By doing so, we could evaluate how the current
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concept of ROC as a chronic disease affected the choice of
systemic therapies.
Patients and methods
The Basel Ovarian Carcinoma Data Base is comprised of
extensive data concerning clinical, histo- and pathomor-
phologic features and treatment characteristics of all
patients whose primary epithelial ovarian cancer was
diagnosed in the canton Basel-Stadt (Basel, Switzerland)
since 1985. For this study, we considered the data from
patients who were initially diagnosed with ROC from 1990
to 2006. Most of the patients had International Federation
of Gynecology and Obstetrics (FIGO) stages I–III at initial
diagnosis (n = 121). In the remaining 12 patients who
were classified as having stage IV disease, the grouping
into this stage was based only on the diagnosis of pleural
involvement and/or liver parenchymal metastases; patients
with other distant metastases (lesions beyond the abdomi-
nal cavity) were excluded from analysis. Since the use of
palliative chemotherapy options was the crucial factor
evaluated in this study, we did not include patients for
whom the choice of possible treatment options were lim-
ited by advanced age (older than 75 years).
Ultimately, 133 patients were analyzed in this study. No
patient was lost to follow-up and we could provide com-
plete information regarding palliative therapy course and
outcome for all patients. Information concerning palliative
treatment was obtained from 12 oncologic units in Swit-
zerland, as well as neighboring regions in Germany and
France. The patients were followed until death or, if they
remained alive and disease-free, for a minimum of 24
months (conclusion of the data collection in July 2008).
It was the goal of our study to give a general overview
regarding the actual administered therapies in the systemic
treatment of ROC and to demonstrate changes and devel-
opments over time. Therefore, we compared the therapy
course and outcome of women whose recurrent disease was
diagnosed up to and including 1997 (group A n = 70) with
those whose recurrent disease was diagnosed after 1997
(group B n = 63). We listed the number of therapy lines
and noted the agents administered. Furthermore, the dura-
tion of each therapy line, and importantly the cumulative
time of treatment, was recorded for each patient. In our
study, survival was defined as the interval from the date of
diagnosis of ROC to the date of death. In this manner, the
recurrent disease-specific survival (RDSS) was calculated.
To evaluate the role of the duration of systemic treat-
ment on survival time in ROC, we calculated the ratio
between cumulative time of therapy (TT) and survival time
(ST), and expressed this as a percentage:
TT  100
ST
For example, a patient who survived 16 months (64 weeks)
and received chemotherapy for a total of 24 weeks would
have a treatment time to survival time (TT/ST) ratio of
37.5. This means that systemic treatment had been
administered for 37.5% of the patient’s survival time.
For this particular purpose, we analyzed only the
patients who ultimately died of their recurrent disease. In
other words, we analyzed only completed treatment cour-
ses and excluded patients who were still alive at the
conclusion of the observation period (i.e., whose therapies
were presumably still ongoing).
The study design and data collection methods were
approved by our institutional review board.
Statistical analysis
To predict the survival with ROC (RDSS), we used
the Kaplan–Meier method. Patients who were alive at the
conclusion of the observation period were censored in the
statistical analyses. Statistical differences between groups
in terms of survival curves were analyzed using the log
rank test. To compare ordinal variables (number of therapy
lines) between the two study groups, the nonparametric
Wilcoxon test was performed. The calculation of the TT/
ST-ratio was made by the Welch two sample t-test. Com-
parisons between nominal parameters were made with the
Fisher exact test. A P value \0.05 was considered signif-
icant. For significant values, the odds ratio (OR) and the
corresponding 95% confidence interval (CI) were reported.
Statistical analyses were performed with R Development
Core Team software, version 2.7.0 (Vienna, Austria).
Results
The clinicopathologic and outcome characteristics of the
133 patients with ROC included in the study are summa-
rized in Tables 1 and 2. The majority of the patients with
ROC included in this study died of the disease (group A
n = 70, 100%; group B: n = 57, 90.5%). Six patients in
group B were alive at the conclusion of the observation
period; four of them have ongoing palliative therapies. In
two further patients, localized recurrent disease was diag-
nosed. In one case, a 47-year old woman had a recurrent
tumor mass in the pelvis, which was surgically removed
(no postoperative residual disease), and postoperatively
received a second-line chemotherapy with six cycles of
carboplatin and paclitaxel. The other patient had a histo-
logically proven recurrence as a fixed pelvic mass eroding
the vaginal mucosa. This 74-year old patient was treated
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with six cycles of carboplatin as monotherapy. These two
patients have experienced a long asymptomatic period (49
and 55 months) up until the conclusion of the observation
period; one might even consider them as potentially cured.
Two patients in study group A had isolated brain metas-
tases, i.e., no recurrent disease in the abdominal region.
These patients received only radiotherapy. All other
patients included in the study had recurrence in abdominal
sites as a manifestation of recurrent disease.
A comparison between both groups in terms of RDSS
showed similar findings (Fig. 1; P = 0.549). The 1-year
adjusted survival rate was 65.7% for patients whose ROC
was diagnosed before 1998 (group A) compared to 69.8%
in those whose ROC was diagnosed later (group B); the
3-year rates were 20.0 and 22.6%, and the 5-year rates were
7.1 and 7.7%, respectively. The median RDSS time was 18
months in group A and 19 months in group B.
Tables 3 and 4 indicate which systemic therapies the
patients in each group received, as well as the number of
lines administered. In group B, representing the current
therapy situation, significantly fewer combination therapies
were administered compared to group A (12.0% vs. 24.1%;
OR 0.43; 95% CI 0.23–0.81; P = 0.0057). The patients in
group B received slightly more therapy lines, but this did
not reach statistical significance (median number of lines 3
vs. 2, mean 2.73 vs. 2.35; P = 0.139). In group B, there
were significantly more patients who received at least three
therapy lines (56.1% vs. 31.1%; OR 3.10; 95% CI 1.37–
7.17; P = 0.005).
Analysis of the TT/ST-ratio showed that the patients
in group B had significantly longer TT in relation to
the survival time (mean value in group A 47.5, mean
value in group B 57.5; difference of the mean values
B–A = -10.02; 95% CI -17.99 to -2.05; P = 0.014).
Table 1 Clinicopathologic and outcome characteristics of 133
patients with recurrent ovarian carcinoma
Variable Group A Group B
Entire group, n (%) 70 (100) 63 (100)
FIGO stage at initial diagnosis
Stage I 5 (7.1) 3 (4.8)
Stage II 14 (20.0) 5 (8.0)
Stage III 44 (62.9) 50 (79.3)
Stage IV 7 (10.0) 5 (7.9)
Histologic subtype
Serous 48 (68.6) 49 (77.8)
Mucinous 4 (5.7) 2 (3.2)
Endometriod 15 (21.4) 8 (12.7)
Clear-cell 3 (4.3) 4 (6.3)
Postoperative chemotherapy (CT)
Platinum-based CT 64 (91.5) 61 (96.8)
CT without platinum compounds 5 (7.1) –
No CT 1 (1.4) 2 (3.2)
Relapse free period
\6 months 29 (41.4) 23 (36.5)
C6 months 41 (58.6) 40 (63.5)
Age at diagnosis of recurrent disease
Mean (range) 58.6 years
(36–75)
58.2 years
(29–75)
B59 years 34 (48.6) 32 (50.8)
60–75 36 (51.4) 31 (49.2)
Outcome status
Died of ovarian cancer 70 (100) 57 (90.5)
Died of other causes – –
Alive (ongoing therapy with
evident disease)
– 4 (6.3)
Alive (no evidence of disease [48
months)
– 2 (3.2)
Group A recurrent disease first diagnosed 1990–1997, n = 70
Group B recurrent disease first diagnosed 1998–2006, n = 63
CT chemotherapy, FIGO International Federation of Gynecology and
Obstetrics
Table 2 Survival time after diagnosis of recurrent disease of the
patients who died of ovarian carcinoma
Group A Group B
\6 months 11 (15.7) 7 (12.3)
6–12 months 13 (18.6) 12 (21.1)
13–24 months 22 (31.4) 18 (31.6)
25–48 months 15 (21.4) 17 (29.8)
[48 months 9 (12.9) 3 (5.3)
Median survival time (range) 18 months (1–129) 19 months
(1–102)
Group A recurrent disease first diagnosed 1990–1997, n = 70
Group B recurrent disease first diagnosed 1998–2006, n = 57
Fig. 1 Recurrent disease-specific survival among 133 patients with
recurrent ovarian carcinoma. Group A recurrent disease first diag-
nosed 1990–1997, n = 70; group B recurrent disease first diagnosed
1998–2006, n = 63
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Discussion
The leading chronic diseases in developed countries
include disorders such as cardiovascular diseases (e.g.,
high blood pressure, stroke), diabetes, obesity, arthritis,
respiratory ailments (e.g., emphysema and bronchial
asthma) and neurologic diseases (e.g., epilepsy and multi-
ple sclerosis). Chronic diseases are by definition long-
lasting or recurrent, i.e., require a long period of treatment,
supervision, observation or care; they are caused by non-
reversible pathological alterations, leave residual disability,
and can be altered but not be cured by medication [9, 10].
A therapeutic goal in the management of chronic diseases
is long-term stabilization with good tolerance to drugs that
have limited cumulative toxicity.
Although in principle, most metastatic malignancies can
also be considered as chronic diseases due to their incur-
able nature, the term ‘‘chronic disease’’ is usually not used
for most malignant diseases in oncologic reviews; it is,
however, specifically mentioned in the current literature
concerning ROC [1–3]. However, it is not discussed in
more detail how this current concept affects specifically the
clinical management of ROC patients. Clinical trials con-
cerning the systemic therapy of ROC usually have not
considered the concept of it as a chronic disease process
(overview in [1, 3–8]). They evaluated mostly therapy
options in the second-line treatment setting, in other words,
only at the beginning of the ROC period. Only a few trials
have evaluated the clinical efficacy of third-, fourth- or
fifth-line therapies [11].
Our study aimed to highlight the current developments
in the management of ROC, which justify its consideration
as a chronic disease and focused on the changes in systemic
therapy of ROC over time. In order to evaluate the treat-
ment course of a chronic disease, it is essential to give an
overview of the entire course of the disease. This was
achieved in our study through the analysis of a population-
based study cohort. Since there has been considerable
change in the last two decades in the number and type of
agents available, we divided the patients of our study group
into two subgroups according to the date of initial diag-
nosis of recurrent disease.
The first main result of our study showed that survival
times of patients with ROC had not improved over the
entire study period. However, this initially disappointing
finding should not necessarily be viewed with undue pes-
simism regarding the therapy of ROC. Particularly, one
should not interpret this as meaning that there have been no
improvements or progress in the treatment of patients with
ROC. The primary goal of palliative treatment includes not
only prolongation of survival, but, just as importantly, the
prevention and relief of symptoms, and maintenance or
improvement of quality of life. Our analysis of the
administered agents showed that, in the more recent study
period (study group B treatment since 1998), a similar
Table 3 Number of therapy lines received by patients who died of
recurrent ovarian carcinoma
Group A Group B
Total no. of patients, n (%) 70 (100) 57 (100)
No systemic therapy 6 (8.6) 5 (8.8)
One therapy line 17 (24.3) 11 (19.3)
Two therapy lines 25 (35.7) 9 (15.8)
Three therapy lines 7 (10.0) 14 (24.6)
Four therapy lines 10 (14.3) 9 (15.8)
Five therapy lines 1 (1.4) 6 (10.5)
Six therapy lines 3 (4.3) 2 (3.5)
Seven therapy lines – 1 (1.7)
Nine therapy lines 1 (1.4) –
Group A: recurrent disease first diagnosed 1990–1997, n = 70
Group B: recurrent disease first diagnosed 1998–2006, n = 57
Table 4 Agents administered for the treatment of recurrent ovarian
carcinoma. List includes also patients with ongoing therapies
Group A Group B
Agent, %
Carboplatin 34.7 31.0
Liposomal doxorubicin 2.0 19.7
Paclitaxel 14.6 10.7
Gemcitabine 3.0 19.2
Topotecan 2.5 9.1
Melphalan 14.6 –
Cyclophosphamid 10.1 1.1
Cisplatin 4.0 1.1
5-Fluoruracil 2.5 –
Capecitabine 1.0 1.1
Docetaxel 1.0 –
Folinic acid 1.5 –
Etoposid 1.5 1.1
Vinorelbine – 1.6
Aflibercept (VEGF trap) – 1.1
Adriblastin – 1.1
Treosulfan – 1.6
Others 2.0 –
Intraperitoneal chemotherapy
Carboplatin 1.5 0.5
Cisplatin 2.0 –
5-Fluoruracil 2.0 –
Others 1.0 –
Group A recurrent disease first diagnosed 1990–1997, n = 70
Group B recurrent disease first diagnosed 1998–2006, n = 63
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survival time with significantly fewer combination thera-
pies and with longer treatment periods (i.e., higher TT/ST
values) could be achieved. Both of these findings suggest
that the administration of less aggressive treatment regi-
mens resulted in similar outcomes. Clearly, the avoidance
of combination therapies and the increased use of mono-
therapies reduce treatment-related toxicities; furthermore,
longer treatment periods and the administration of more
therapy lines (in study group B, 56% of the patients
received more than two therapy lines) are possible only
when the quality of life has not been intolerably affected.
In accordance with other authors, we believe that choosing
agents with few or tolerable toxicities that can be given on
a convenient schedule over a prolonged period of time is an
acceptable way to manage ROC [3]; however, controversy
exists regarding an appropriate time to stop such therapy.
Since improvements in palliative therapy do not only
imply extended survival but also improved overall quality
of life, current treatment strategies may very well reflect
improvements in the systemic palliative treatment of
patients with ROC. Furthermore, when a disease which
requires periodic chemotherapy to control progressive
course and symptoms is increasingly treated with a strategy
that permits stabilization and uses regimens that have
limited cumulative toxicity, then the requirements of a
chronic disease management have been fulfilled [1].
We think that the paradigm shift in the palliative treat-
ment of ROC as chronic disease cannot be attributed to a
certain date or the introduction of a single agent or regi-
men. In clinical reality, there is often a slow shift or
interplay between theory and the therapy options that
might result in a significant change in the general regard
of a disease. Improvements in the systemic treatment
of ROC are surely associated with the introduction of a
new generation of cytotoxic agents, above all, liposomal
doxorubicin, gemcitabine and topotecan. As demonstrated
in Table 4, while platinum and paclitaxel remained viable
options in the systemic treatment of ROC, these modern
agents made up approximately 48% of therapies in patients
whose ROC was diagnosed after 1997, while in the pre-
ceding period only 7%. Certain drugs which were used in
the earlier study group (e.g., melphalan, cyclophosphamid
and cisplatin) have mostly been replaced. Undoubtedly,
through the selection of modern drugs with safer profiles,
and of course through considerable advances in supportive
care, the therapy concepts of chronic disease can be better
implemented today compared to earlier times.
One limitation of our study must be considered: we did not
distinguish between the prognostically relevant subgroups of
platinum-resistant and platinum-sensitive patients. These
specific definitions are essential for clinical trials to ensure
uniformity of design and patient selection. From a clinical
perspective, however, these definitions may be arbitrary [1].
The principle of second-line therapy is that if the treatment is
successful, patients will eventually have another recurrence
and undergo additional rounds of therapy. In this sense,
platinum-sensitive and resistant disease are not necessarily
different entities in terms of the concept of a chronic disease.
In the palliative setting, there is currently no agreed
upon approach for the treatment of this heterogeneous
group of ROC patients [12]. With respect to ROC as a
chronic disease, it is interesting to observe the controver-
sies surrounding the optimal second-line treatment of
platinum-sensitive patients. The question is whether these
patients should be offered a single-agent treatment (plati-
num alone) or a combination therapy (platinum plus
another agent, e.g., paclitaxel [13], gemcitabine [14] or
liposomal doxorubicin [15]. Some authors support the
administration of combination therapies, since they result
in improved response rates and progression-free survival
compared with single-agent platinum [1, 4]. Others are
more critical concerning the use of combination therapies
and feel that the improvement in response is at the cost of
toxicity and quality of life [2, 3, 5, 6, 16]. Furthermore,
combination therapies may not have much of a clinically
apparent advantage compared with sequential single-agent
therapy with regard to overall survival, and it may be
possible to achieve the same efficacy by sequencing plat-
inum and other agents without the increase in toxicities
observed with combination therapy [3, 5, 6]. Particularly,
with respect to the increasing use of subsequent therapy
lines, it must be emphasized that patients with a history of
severe side effects associated with previous treatment
might be poorer candidates for further treatments [1].
Considering ROC in the context of chronic disease, it
must be pointed out that clinical trials evaluating combi-
nation therapies vs. monotherapy report overall survival
rates, but they do not report the number of subsequent
therapy lines and the choice of agents given after the trial up
until death [13–15]. The use of multiple therapies after the
completion of a randomized study in ROC might obscure
the benefit of combination therapy [16]. Since these studies
encompass only a fraction of the chronic disease process,
their results cannot be completely applied toward the entire
course of disease and therapy. In our opinion, the increased
application of monotherapies reflects better the concept of
ROC as a chronic disease. We prefer administering com-
bination therapies only for highly symptomatic patients. In
these cases, the high response rates of the regimen result in
rapid alleviation of severe disease-related symptoms and
justifies the acceptance of increased toxicity.
In conclusion, we believe that is the first study to depict
a population-based image of the palliative treatment situ-
ation in ROC and demonstrates how far the concept of
ROC as a chronic disease has been implemented in clinical
practice. We support the hope that through the availability
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and use of newer and more effective systemic agents,
including both traditional cytotoxic regimens and new
promising targeted biologic agents, the treatment of these
patients can be further improved. Future studies should
examine not only individual agents or differences between
single-agent and combination therapies, but also specific
treatment strategies with more than one therapy line over a
longer course of time with respect to the concept of ROC as
a chronic disease.
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